FDA recalls shrimp sold at Walmart
Digest more
The Food and Drug Administration has authorized emergency use of animal drugs to treat and prevent infestations of the New World Screwworm, which poses an emerging threat to U.S. livestock and food security.
A little boy in the Chicago area is battling a rare disease and desperately needs a drug treatment for a better life. The drug has not been FDA approved, and it could disappear if it isn't soon.
15h
The Well News on MSNFDA Cleared to Use Animal Drugs to Combat New World Screwworm Threat
WASHINGTON - The Food and Drug Administration was authorized Tuesday to use "animal drugs" on an emergency basis to treat and prevent infestations of the New World screwworm, a flesh-eating parasite that poses a threat to the U.
The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' oral medication for a rare genetic disorder with limited treatment options, the company said on Tuesday.
A series of panels convened by the Food and Drug Administration is raising concerns that the agency is skirting federal rules and promoting fringe views about antidepressants and other products.
The Food and Drug Administration (FDA) became authorized Tuesday to allow the use of animal drugs to treat or prevent infestations caused by the New World screwworm, a flesh-eating parasite that has recently disrupted the cattle industry.
More than 5,000 pounds of cheese products made by Middlefield Original Cheese Co‑op are being voluntarily recalled after the company discovered contamination by potentially deadly bacteria, according to the Food and Drug Administration.
More than 60 percent of US drug facilities are in areas with weather disasters.
The 5th Circuit ruled on Aug. 16 that it would limit access to mifepristone, finding that the Food and Drug Administration overstepped its authority with a series of actions that made it easier ...
The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency’s concerns and now sees potential for a speedy review.
20h
Pharmaceutical Technology on MSNFDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab brengitecan (iza-bren) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor mutations.